Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Immunovant, Inc.IMVT · Entity 3632 | Chief Development Officer | August 21, 2024 | August 23, 2024 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Immunovant, Inc.
Report date August 21, 2024 · Filed August 23, 2024
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 440,959 |
Ending reported balance
After 2024-08-21 transaction · row 2
2 source rows · reconciled sequenceRow 1 · 2024-08-21 · Sale · Disposed 2,907 · Balance 441,079 F1: On August 17, 2022, the holder was granted 112,816 restricted stock units ("RSUs"), as previously reported on a Form 4 filed on August 19, 2022, of which 7,051 of these RSUs vested on August 17, 2024. The sale reported on this Form 4 represents shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting and settlement of these RSUs. The sale is mandated by the Issuer's election to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary transaction by the Reporting Person. F2: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $31.26 - $32.25 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote to this Form 4. Row 2 · 2024-08-21 · Sale · Disposed 120 · Balance 440,959 F1: On August 17, 2022, the holder was granted 112,816 restricted stock units ("RSUs"), as previously reported on a Form 4 filed on August 19, 2022, of which 7,051 of these RSUs vested on August 17, 2024. The sale reported on this Form 4 represents shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting and settlement of these RSUs. The sale is mandated by the Issuer's election to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary transaction by the Reporting Person. F3: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $32.28 - $32.37 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote to this Form 4. |
Filing footnotes · ownership attribution and instrument terms
F1: On August 17, 2022, the holder was granted 112,816 restricted stock units ("RSUs"), as previously reported on a Form 4 filed on August 19, 2022, of which 7,051 of these RSUs vested on August 17, 2024. The sale reported on this Form 4 represents shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting and settlement of these RSUs. The sale is mandated by the Issuer's election to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary transaction by the Reporting Person.
F2: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $31.26 - $32.25 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote to this Form 4.
F3: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $32.28 - $32.37 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote to this Form 4.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| August 21, 2024 Filed Aug 23, 2024 20:10 UTC | Immunovant, Inc. IMVT · Entity 3632 | SaleCommon Stock | 120 | $32.32 | $3,878.40 |
DisclosureSEC source: 0001764013-24-000157 · wk-form4_1724443813.xml · nonDerivative · entry 2 Butchko Julia G. · CIK 0001796290 · Chief Development Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 440,959 F1 · shares: On August 17, 2022, the holder was granted 112,816 restricted stock units ("RSUs"), as previously reported on a Form 4 filed on August 19, 2022, of which 7,051 of these RSUs vested on August 17, 2024. The sale reported on this Form 4 represents shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting and settlement of these RSUs. The sale is mandated by the Issuer's election to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary transaction by the Reporting Person. F3 · price: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $32.28 - $32.37 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote to this Form 4. Read SEC document |
| August 21, 2024 Filed Aug 23, 2024 20:10 UTC | Immunovant, Inc. IMVT · Entity 3632 | SaleCommon Stock | 2,907 | $31.84 | $92,558.88 |
DisclosureSEC source: 0001764013-24-000157 · wk-form4_1724443813.xml · nonDerivative · entry 1 Butchko Julia G. · CIK 0001796290 · Chief Development Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 441,079 F1 · shares: On August 17, 2022, the holder was granted 112,816 restricted stock units ("RSUs"), as previously reported on a Form 4 filed on August 19, 2022, of which 7,051 of these RSUs vested on August 17, 2024. The sale reported on this Form 4 represents shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting and settlement of these RSUs. The sale is mandated by the Issuer's election to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary transaction by the Reporting Person. F2 · price: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $31.26 - $32.25 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote to this Form 4. Read SEC document |
| July 17, 2024 Filed Jul 19, 2024 21:38 UTC | Immunovant, Inc. IMVT · Entity 3632 | SaleCommon Stock | 169 | $30.55 | $5,162.95 |
DisclosureSEC source: 0001764013-24-000134 · wk-form4_1721425076.xml · nonDerivative · entry 2 Butchko Julia G. · CIK 0001796290 · Chief Development Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 443,986 F1 · shares: On April 12, 2023, the holder was granted 100,188 restricted stock units ("RSUs"), as previously reported on a Form 4 filed on April 14, 2023, of which 6,261 of these RSUs vested on July 12, 2024. The sale reported on this Form 4 represents shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting and settlement of these RSUs. The sale is mandated by the Issuer's election to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary transaction by the Reporting Person. F3 · price: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $30.30 - $30.84 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote to this Form 4. Read SEC document |
| July 17, 2024 Filed Jul 19, 2024 21:38 UTC | Immunovant, Inc. IMVT · Entity 3632 | SaleCommon Stock | 2,698 | $29.64 | $79,968.72 |
DisclosureSEC source: 0001764013-24-000134 · wk-form4_1721425076.xml · nonDerivative · entry 1 Butchko Julia G. · CIK 0001796290 · Chief Development Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 444,155 F1 · shares: On April 12, 2023, the holder was granted 100,188 restricted stock units ("RSUs"), as previously reported on a Form 4 filed on April 14, 2023, of which 6,261 of these RSUs vested on July 12, 2024. The sale reported on this Form 4 represents shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting and settlement of these RSUs. The sale is mandated by the Issuer's election to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary transaction by the Reporting Person. F2 · price: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $29.30 - $30.28 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote to this Form 4. Read SEC document |
| July 09, 2024 Filed Jul 10, 2024 21:06 UTC | Immunovant, Inc. IMVT · Entity 3632 | SaleCommon Stock | 1,527 | $28.06 | $42,847.62 |
DisclosureSEC source: 0001764013-24-000126 · wk-form4_1720645577.xml · nonDerivative · entry 1 Butchko Julia G. · CIK 0001796290 · Chief Development Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 446,853 F1 · shares: On March 19, 2021, the holder was granted 54,500 restricted stock units ("RSUs"), as previously reported on a Form 4 filed on March 23, 2021, of which 3,406 of these RSUs vested on July 1, 2024. The sale reported on this Form 4 represents shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting and settlement of these RSUs. The sale is mandated by the Issuer's election to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary transaction by the Reporting Person. F2 · price: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $27.48 - $28.42 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote to this Form 4. Read SEC document |
| May 22, 2024 Filed May 24, 2024 20:14 UTC | Immunovant, Inc. IMVT · Entity 3632 | SaleCommon Stock | 3,247 | $29.65 | $96,273.55 |
DisclosureSEC source: 0001764013-24-000097 · wk-form4_1716581663.xml · nonDerivative · entry 1 Butchko Julia G. · CIK 0001796290 · Chief Development Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 448,380 F1 · shares: On August 17, 2022, the holder was granted 112,816 restricted stock units ("RSUs"), as previously reported on a Form 4 filed on August 19, 2022, of which 7,051 of these RSUs vested on May 17, 2024. The sale reported on this Form 4 represents shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting and settlement of these RSUs. The sale is mandated by the Issuer's election to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary transaction by the Reporting Person. F2 · price: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $29.31 - $30.02 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote to this Form 4. Read SEC document |
| April 17, 2024 Filed Apr 19, 2024 21:59 UTC | Immunovant, Inc. IMVT · Entity 3632 | SaleCommon Stock | 2,290 | $29.94 | $68,562.60 |
DisclosureSEC source: 0001764013-24-000077 · wk-form4_1713563949.xml · nonDerivative · entry 2 Butchko Julia G. · CIK 0001796290 · Chief Development Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 451,627 F1 · shares: On April 12, 2023, the holder was granted 100,188 restricted stock units ("RSUs"), as previously reported on a Form 4 filed on April 14, 2023, of which 25,047 of these RSUs vested on April 12, 2024. The sale reported on this Form 4 represents shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting and settlement of these RSUs. The sale is mandated by the Issuer's election to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary transaction by the Reporting Person. F3 · price: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $29.43 - $30.20 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote to this Form 4. Read SEC document |
| April 17, 2024 Filed Apr 19, 2024 21:59 UTC | Immunovant, Inc. IMVT · Entity 3632 | SaleCommon Stock | 7,825 | $28.80 | $225,360.00 |
DisclosureSEC source: 0001764013-24-000077 · wk-form4_1713563949.xml · nonDerivative · entry 1 Butchko Julia G. · CIK 0001796290 · Chief Development Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 453,917 F1 · shares: On April 12, 2023, the holder was granted 100,188 restricted stock units ("RSUs"), as previously reported on a Form 4 filed on April 14, 2023, of which 25,047 of these RSUs vested on April 12, 2024. The sale reported on this Form 4 represents shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting and settlement of these RSUs. The sale is mandated by the Issuer's election to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary transaction by the Reporting Person. F2 · price: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $28.43 - $29.40 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote to this Form 4. Read SEC document |
| April 09, 2024 Filed Apr 10, 2024 20:16 UTC | Immunovant, Inc. IMVT · Entity 3632 | SaleCommon Stock | 1,053 | $31.18 | $32,832.54 |
DisclosureSEC source: 0001764013-24-000071 · wk-form4_1712780175.xml · nonDerivative · entry 1 Butchko Julia G. · CIK 0001796290 · Chief Development Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 461,742 F1 · shares: On March 19, 2021, the holder was granted 54,500 restricted stock units ("RSUs"), as previously reported on a Form 4 filed on March 23, 2021, of which 3,406 of these RSUs vested on April 1, 2024. The sale reported on this Form 4 represents shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting and settlement of these RSUs. The sale is mandated by the Issuer's election to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary transaction by the Reporting Person. F2 · price: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $30.73 - $31.45 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote to this Form 4. Read SEC document |
| April 02, 2024 Filed Apr 4, 2024 20:29 UTC | Immunovant, Inc. IMVT · Entity 3632 | GrantStock Option (right to buy) · Derivative | 68,723 | $0.00 Strike: $30.78 | $0.00 |
DisclosureSEC source: 0001764013-24-000048 · wk-form4_1712262541.xml · derivative · entry 2 Butchko Julia G. · CIK 0001796290 · Chief Development Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 68,723 Underlying: Common Stock · 68,723 shares Expires 2034-04-02 F2 · derivative.exercise_date: The shares underlying the options will vest as to 25% of the shares on April 2, 2025 and the remainder will vest in 36 substantially equal monthly installments over three years thereafter, subject to the Reporting Person's continuous service to the Issuer as of such date. Read SEC document |
| April 02, 2024 Filed Apr 4, 2024 20:29 UTC | Immunovant, Inc. IMVT · Entity 3632 | GrantCommon Stock | 54,978 | $0.00 | $0.00 |
DisclosureSEC source: 0001764013-24-000048 · wk-form4_1712262541.xml · nonDerivative · entry 1 Butchko Julia G. · CIK 0001796290 · Chief Development Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 462,795 F1 · shares: These restricted stock units ("RSUs") were granted pursuant to the Issuer's 2019 Equity Incentive Plan. Each RSU represents a contingent right to receive one share of common stock upon the vesting of the unit. The RSUs will vest as to 25% of the units on April 2, 2025, and the remainder will vest in substantially equal installments on a quarterly basis over three years thereafter, subject to the Reporting Person's continuous service to the Issuer as of such date. Read SEC document |
| February 22, 2024 Filed Feb 23, 2024 21:14 UTC | Immunovant, Inc. IMVT · Entity 3632 | SaleCommon Stock | 2,146 | $36.15 | $77,577.90 |
DisclosureSEC source: 0001764013-24-000038 · wk-form4_1708722860.xml · nonDerivative · entry 1 Butchko Julia G. · CIK 0001796290 · Chief Development Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 407,817 F1 · security: On August 17, 2022, the holder was granted 112,816 restricted stock units ("RSUs"), as previously reported on a Form 4 filed on August 19, 2022, of which 7,051 of these RSUs vested on February 17, 2024. Amounts reported herein represent shares sold by the holder solely to satisfy the holder's tax withholding obligation due in connection with the vesting and settlement of this tranche of the RSUs and do not represent a discretionary sale by the holder. F2 · price: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $35.85 - $36.60 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote to this Form 4. Read SEC document |
| January 05, 2024 Filed Jan 9, 2024 21:20 UTC | Immunovant, Inc. IMVT · Entity 3632 | SaleCommon Stock | 1,297 | $38.59 | $50,051.23 |
DisclosureSEC source: 0001764013-24-000007 · wk-form4_1704835205.xml · nonDerivative · entry 1 Butchko Julia G. · CIK 0001796290 · Chief Development Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 409,963 F1 · security: On March 19, 2021, the holder was granted 54,500 restricted stock units ("RSUs"), as previously reported on a Form 4 filed on March 23, 2021, of which 3,407 of these RSUs vested on January 1, 2024. Amounts reported herein represent shares sold by the holder solely to satisfy the holder's tax withholding obligation due in connection with the vesting and settlement of this tranche of the RSUs and do not represent a discretionary sale by the holder. F2 · price: The price reported is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $38.59 - $39.27 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote to this Form 4. Read SEC document |
| November 22, 2023 Filed Nov 24, 2023 19:47 UTC | Immunovant, Inc. IMVT · Entity 3632 | SaleCommon Stock | 124 | $33.52 | $4,156.48 |
DisclosureSEC source: 0001764013-23-000141 · wk-form4_1700855261.xml · nonDerivative · entry 2 Butchko Julia G. · CIK 0001796290 · Chief Development Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 411,260 F1 · security: On August 17, 2022, the holder was granted 112,816 restricted stock units ("RSUs"), as previously reported on a Form 4 filed on August 19, 2022, of which 7,051 of these RSUs vested on November 17, 2023. Amounts reported herein represent shares sold by the holder solely to satisfy the holder's tax withholding obligation due in connection with the vesting and settlement of this tranche of the RSUs and do not represent a discretionary sale by the holder. F3 · price: The price reported is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $33.46 - $33.68 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote to this Form 4. Read SEC document |
| November 22, 2023 Filed Nov 24, 2023 19:47 UTC | Immunovant, Inc. IMVT · Entity 3632 | SaleCommon Stock | 3,141 | $32.75 | $102,867.75 |
DisclosureSEC source: 0001764013-23-000141 · wk-form4_1700855261.xml · nonDerivative · entry 1 Butchko Julia G. · CIK 0001796290 · Chief Development Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 411,384 F1 · security: On August 17, 2022, the holder was granted 112,816 restricted stock units ("RSUs"), as previously reported on a Form 4 filed on August 19, 2022, of which 7,051 of these RSUs vested on November 17, 2023. Amounts reported herein represent shares sold by the holder solely to satisfy the holder's tax withholding obligation due in connection with the vesting and settlement of this tranche of the RSUs and do not represent a discretionary sale by the holder. F2 · price: The price reported is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $32.43 - $33.38 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote to this Form 4. Read SEC document |
| October 05, 2023 Filed Oct 6, 2023 21:15 UTC | Immunovant, Inc. IMVT · Entity 3632 | SaleCommon Stock | 1,439 | $36.39 | $52,365.21 |
DisclosureSEC source: 0001764013-23-000118 · wk-form4_1696626899.xml · nonDerivative · entry 2 Butchko Julia G. · CIK 0001796290 · Chief Development Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 414,525 F1 · security: On March 19, 2021, the holder was granted 54,500 restricted stock units ("RSUs"), as previously reported on a Form 4 filed on March 23, 2021, of which 3,406 of these RSUs vested on October 1, 2023. Amounts reported herein represent shares sold by the holder solely to satisfy the holder's tax withholding obligation due in connection with the vesting and settlement of this tranche of the RSUs and do not represent a discretionary sale by the holder. F3 · price: The price reported is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $35.92 - $36.83 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote to this Form 4 Read SEC document |
| October 05, 2023 Filed Oct 6, 2023 21:15 UTC | Immunovant, Inc. IMVT · Entity 3632 | SaleCommon Stock | 296 | $35.54 | $10,519.84 |
DisclosureSEC source: 0001764013-23-000118 · wk-form4_1696626899.xml · nonDerivative · entry 1 Butchko Julia G. · CIK 0001796290 · Chief Development Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 415,964 F1 · security: On March 19, 2021, the holder was granted 54,500 restricted stock units ("RSUs"), as previously reported on a Form 4 filed on March 23, 2021, of which 3,406 of these RSUs vested on October 1, 2023. Amounts reported herein represent shares sold by the holder solely to satisfy the holder's tax withholding obligation due in connection with the vesting and settlement of this tranche of the RSUs and do not represent a discretionary sale by the holder. F2 · price: The price reported is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $34.90 - $35.89 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote to this Form 4. Read SEC document |
| August 24, 2023 Filed Aug 25, 2023 21:00 UTC | Immunovant, Inc. IMVT · Entity 3632 | SaleCommon Stock | 1 | $20.89 | $20.89 |
DisclosureSEC source: 0001764013-23-000101 · wf-form4_169299721638735.xml · nonDerivative · entry 2 Butchko Julia G. · CIK 0001796290 · Chief Development Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 416,260 F1 · security: On August 17, 2022, the holder was granted 112,816 restricted stock units ("RSUs"), as previously reported on a Form 4 filed on August 19, 2022, of which 28,204 of these RSUs vested on August 17, 2023. Amounts reported herein represent shares sold by the holder solely to satisfy the holder's tax withholding obligation due in connection with the vesting and settlement of this tranche of the RSUs and do not represent a discretionary sale by the holder. Read SEC document |
| August 24, 2023 Filed Aug 25, 2023 21:00 UTC | Immunovant, Inc. IMVT · Entity 3632 | SaleCommon Stock | 12,332 | $20.30 | $250,339.60 |
DisclosureSEC source: 0001764013-23-000101 · wf-form4_169299721638735.xml · nonDerivative · entry 1 Butchko Julia G. · CIK 0001796290 · Chief Development Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 416,261 F1 · security: On August 17, 2022, the holder was granted 112,816 restricted stock units ("RSUs"), as previously reported on a Form 4 filed on August 19, 2022, of which 28,204 of these RSUs vested on August 17, 2023. Amounts reported herein represent shares sold by the holder solely to satisfy the holder's tax withholding obligation due in connection with the vesting and settlement of this tranche of the RSUs and do not represent a discretionary sale by the holder. F2 · price: The price reported is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $19.87 - $20.85 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote to this Form 4. Read SEC document |
| July 12, 2023 Filed Jul 13, 2023 21:10 UTC | Immunovant, Inc. IMVT · Entity 3632 | SaleCommon Stock | 1,470 | $19.73 | $29,003.10 |
DisclosureSEC source: 0001764013-23-000077 · wf-form4_168928262114322.xml · nonDerivative · entry 1 Butchko Julia G. · CIK 0001796290 · Chief Development Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 428,593 F1 · security: On March 19, 2021, the holder was granted 54,500 restricted stock units ("RSUs"), as previously reported on a Form 4 filed on March 23, 2021, of which 3,406 of these RSUs vested on July 1, 2023. Amounts reported herein represent shares sold by the holder solely to satisfy the holder's tax withholding obligation due in connection with the vesting and settlement of this tranche of the RSUs and do not represent a discretionary sale by the holder. F2 · price: The price reported is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $19.39 - $20.12 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote to this Form 4. Read SEC document |
| April 18, 2023 Filed Apr 19, 2023 20:12 UTC | Immunovant, Inc. IMVT · Entity 3632 | SaleCommon Stock | 1,544 | $15.27 | $23,576.88 |
DisclosureSEC source: 0001764013-23-000051 · wf-form4_168193514282716.xml · nonDerivative · entry 1 Butchko Julia G. · CIK 0001796290 · Chief Development Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 430,063 F1 · security: On March 19, 2021, the holder was granted 54,500 restricted stock units ("RSUs"), as previously reported on a Form 4 filed on March 23, 2021, of which 3,406 of these RSUs vested on April 1, 2023. Amounts reported herein represent shares sold by the holder solely to satisfy the holder's tax withholding obligation due in connection with the vesting and settlement of this tranche of the RSUs and do not represent a discretionary sale by the holder. F2 · price: The price reported is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $15.08 - $15.50 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote to this Form 4. Read SEC document |
| April 12, 2023 Filed Apr 14, 2023 20:26 UTC | Immunovant, Inc. IMVT · Entity 3632 | GrantStock Option (right to buy) · Derivative | 130,081 | $0.00 Strike: $14.70 | $0.00 |
DisclosureSEC source: 0001764013-23-000042 · wf-form4_168150398782671.xml · derivative · entry 2 Butchko Julia G. · CIK 0001796290 · Chief Dev. & Tech. Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 130,081 Underlying: Common Stock · 130,081 shares Expires 2033-04-12 F3 · derivative.exercise_date: Shares underlying the options vest over four years, with 25% of the shares underlying the options vesting on April 12, 2024 and the remainder of the shares underlying the options vesting in 36 equal monthly installments thereafter, subject to the Reporting Person providing continuous service to the Issuer as of each such date. Read SEC document |
| April 12, 2023 Filed Apr 14, 2023 20:26 UTC | Immunovant, Inc. IMVT · Entity 3632 | GrantCommon Stock | 100,188 | $0.00 | $0.00 |
DisclosureSEC source: 0001764013-23-000042 · wf-form4_168150398782671.xml · nonDerivative · entry 1 Butchko Julia G. · CIK 0001796290 · Chief Dev. & Tech. Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 431,607 F1 · security: Represents the number of shares underlying restricted stock units awards ("RSUs"). F2 · shares: The RSUs vest over four years, with 25% of the RSUs vesting on April 12, 2024 and the remainder of the RSUs vesting in 12 equal quarterly installments thereafter, subject to the Reporting Person providing continuous service to the Issuer as of each such date. Read SEC document |
| January 11, 2023 Filed Jan 13, 2023 13:19 UTC | Immunovant, Inc. IMVT · Entity 3632 | SaleCommon Stock | 60,471 | $16.79 | $1,015,308.09 |
DisclosureSEC source: 0001764013-23-000010 · wf-form4_167361594694409.xml · nonDerivative · entry 2 Butchko Julia G. · CIK 0001796290 · Chief Dev. & Tech. Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 331,419 F1 · security: On March 19, 2021, the holder was granted 54,500 restricted stock units ("RSUs"), as previously reported on a Form 4 filed on March 23, 2021, of which 3,407 of these RSUs vested on January 1, 2023. On August 3, 2021, the holder was granted 285,306 RSUs, as previously reported on a Form 4 filed on August 4, 2021, of which the remaining 142,653 of these RSUs vested on January 1, 2023. Amounts reported herein represent shares sold by the holder solely to satisfy the holder's tax withholding obligations due in connection with the vesting and settlement of these tranches of the RSUs and do not represent a discretionary sale by the holder. F2 · price: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $16.68 - $16.80 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote to this Form 4. Read SEC document |
| January 11, 2023 Filed Jan 13, 2023 13:19 UTC | Immunovant, Inc. IMVT · Entity 3632 | SaleCommon Stock | 19 | $15.16 | $288.04 |
DisclosureSEC source: 0001764013-23-000010 · wf-form4_167361594694409.xml · nonDerivative · entry 1 Butchko Julia G. · CIK 0001796290 · Chief Dev. & Tech. Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 391,890 F1 · security: On March 19, 2021, the holder was granted 54,500 restricted stock units ("RSUs"), as previously reported on a Form 4 filed on March 23, 2021, of which 3,407 of these RSUs vested on January 1, 2023. On August 3, 2021, the holder was granted 285,306 RSUs, as previously reported on a Form 4 filed on August 4, 2021, of which the remaining 142,653 of these RSUs vested on January 1, 2023. Amounts reported herein represent shares sold by the holder solely to satisfy the holder's tax withholding obligations due in connection with the vesting and settlement of these tranches of the RSUs and do not represent a discretionary sale by the holder. Read SEC document |
| October 13, 2022 Filed Oct 17, 2022 12:59 UTC | Immunovant, Inc. IMVT · Entity 3632 | SaleCommon Stock | 928 | $9.18 | $8,519.04 |
DisclosureSEC source: 0001764013-22-000132 · wf-form4_166601156720429.xml · nonDerivative · entry 1 Butchko Julia G. · CIK 0001796290 · Chief Dev. & Tech. Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 391,909 F1 · security: On March 19, 2021, the holder was granted 54,500 restricted stock units ("RSUs"), as previously reported on a Form 4 filed on March 23, 2021, of which 3,406 of these RSUs vested on October 1, 2022 and the remainder of the RSUs vest in quarterly installments thereafter, subject to the Reporting Person providing continuous service to the Issuer as of each such date. Amounts reported herein represent shares sold by the holder solely to satisfy the holder's tax withholding obligation due in connection with the vesting and settlement of this tranche of the RSUs and do not represent a discretionary sale by the holder. F2 · price: The price reported is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $9.18 - $9.26 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote to this Form 4. Read SEC document |
| September 28, 2022 Filed Sep 29, 2022 21:09 UTC | Immunovant, Inc. IMVT · Entity 3632 | SaleCommon Stock | 535 | $4.67 | $2,498.45 |
DisclosureSEC source: 0001764013-22-000124 · wf-form4_166448577616322.xml · nonDerivative · entry 1 Butchko Julia G. · CIK 0001796290 · Chief Dev. & Tech. Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 392,837 F1 · security: On March 19, 2021, the holder was granted 54,500 restricted stock units ("RSUs"), as previously reported on a Form 4 filed on March 23, 2021, of which 1,135 of these RSUs vested on September 19, 2022. Amounts reported herein represent shares sold by the holder solely to satisfy the holder's tax withholding obligation due in connection with the vesting and settlement of this tranche of the RSUs and do not represent a discretionary sale by the holder. Read SEC document |
| August 30, 2022 Filed Sep 1, 2022 11:33 UTC | Immunovant, Inc. IMVT · Entity 3632 | SaleCommon Stock | 548 | $5.83 | $3,194.84 |
DisclosureSEC source: 0001764013-22-000111 · wf-form4_166203199206250.xml · nonDerivative · entry 1 Butchko Julia G. · CIK 0001796290 · Chief Dev. & Tech. Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 393,372 F1 · security: On March 19, 2021, the holder was granted 54,500 restricted stock units ("RSUs"), as previously reported on a Form 4 filed on March 23, 2021, of which 1,136 of these RSUs vested on August 19, 2022. Amounts reported herein represent shares sold by the holder solely to satisfy the holder's tax withholding obligation due in connection with the vesting and settlement of this tranche of the RSUs and do not represent a discretionary sale by the holder. Read SEC document |
| August 17, 2022 Filed Aug 19, 2022 20:54 UTC | Immunovant, Inc. IMVT · Entity 3632 | GrantStock Option (right to buy) · Derivative | 169,648 | $0.00 Strike: $4.99 | $0.00 |
DisclosureSEC source: 0001764013-22-000103 · wf-form4_166094246284096.xml · derivative · entry 2 Butchko Julia G. · CIK 0001796290 · Chief Dev. & Tech. Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 169,648 Underlying: Common Stock · 169,648 shares Expires 2032-08-17 F3 · derivative.exercise_date: Shares underlying the options vest over four years, with 25% of the shares underlying the options vesting on August 17, 2023 and the remainder of the shares underlying the options vesting in 36 equal monthly installments thereafter, subject to the Reporting Person providing continuous service to the Issuer as of each such date. Read SEC document |
| August 17, 2022 Filed Aug 19, 2022 20:54 UTC | Immunovant, Inc. IMVT · Entity 3632 | GrantCommon Stock | 112,816 | $0.00 | $0.00 |
DisclosureSEC source: 0001764013-22-000103 · wf-form4_166094246284096.xml · nonDerivative · entry 1 Butchko Julia G. · CIK 0001796290 · Chief Dev. & Tech. Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 393,920 F1 · security: Represents the number of shares underlying restricted stock units awards ("RSUs"). F2 · shares: The RSUs vest over four years, with 25% of the RSUs vesting on August 17, 2023 and the remainder of the RSUs vesting in 12 equal quarterly installments thereafter, subject to the Reporting Person providing continuous service to the Issuer as of each such date. Read SEC document |
| July 27, 2022 Filed Jul 29, 2022 11:38 UTC | Immunovant, Inc. IMVT · Entity 3632 | SaleCommon Stock | 510 | $4.27 | $2,177.70 |
DisclosureSEC source: 0001764013-22-000078 · wf-form4_165909471978803.xml · nonDerivative · entry 1 Butchko Julia G. · CIK 0001796290 · Chief Dev. & Tech. Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 281,104 F1 · security: On March 19, 2021, the holder was granted 54,500 restricted stock units ("RSUs"), as previously reported on a Form 4 filed on March 23, 2021, of which 1,135 of these RSUs vested on July 19, 2022. Amounts reported herein represent shares sold by the holder solely to satisfy the holder's tax withholding obligation due in connection with the vesting and settlement of this tranche of the RSUs and do not represent a discretionary sale by the holder. Read SEC document |
| June 29, 2022 Filed Jul 1, 2022 11:04 UTC | Immunovant, Inc. IMVT · Entity 3632 | SaleCommon Stock | 460 | $4.02 | $1,849.20 |
DisclosureSEC source: 0001764013-22-000071 · wf-form4_165667344261552.xml · nonDerivative · entry 1 Butchko Julia G. · CIK 0001796290 · Chief Dev. & Tech. Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 281,614 F1 · security: On March 19, 2021, the holder was granted 54,500 restricted stock units ("RSUs"), as previously reported on a Form 4 filed on March 23, 2021, of which 1,136 of these RSUs vested on June 19, 2022. Amounts reported herein represent shares sold by the holder solely to satisfy the holder's tax withholding obligation due in connection with the vesting and settlement of this tranche of the RSUs and do not represent a discretionary sale by the holder. F2 · price: The price reported is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $4.02 - $4.04 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote to this Form 4. Read SEC document |
| May 24, 2022 Filed May 25, 2022 20:26 UTC | Immunovant, Inc. IMVT · Entity 3632 | SaleCommon Stock | 492 | $3.79 | $1,864.68 |
DisclosureSEC source: 0001764013-22-000047 · wf-form4_165351034511810.xml · nonDerivative · entry 1 Butchko Julia G. · CIK 0001796290 · Chief Dev. & Tech. Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 282,074 F1 · security: On March 19, 2021, the holder was granted 54,500 restricted stock units ("RSUs"), as previously reported on a Form 4 filed on March 23, 2021, of which 1,135 of these RSUs vested on May 19, 2022. Amounts reported herein represent shares sold by the holder solely to satisfy the holder's tax withholding obligation due in connection with the vesting and settlement of this tranche of the RSUs and do not represent a discretionary sale by the holder. F2 · price: The price reported is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $3.79 - $3.83 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote to this Form 4. Read SEC document |
| April 27, 2022 Filed Apr 29, 2022 11:08 UTC | Immunovant, Inc. IMVT · Entity 3632 | SaleCommon Stock | 541 | $4.72 | $2,553.52 |
DisclosureSEC source: 0001764013-22-000043 · wf-form4_165123049662918.xml · nonDerivative · entry 1 Butchko Julia G. · CIK 0001796290 · Chief Dev. & Tech. Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 282,566 F1 · security: On March 19, 2021, the holder was granted 54,500 restricted stock units ("RSUs"), as previously reported on a Form 4 filed on March 23, 2021, of which 1,135 of these RSUs vested on April 19, 2022. Amounts reported herein represent shares sold by the holder solely to satisfy the holder's tax withholding obligation due in connection with the vesting and settlement of this tranche of the RSUs and do not represent a discretionary sale by the holder. F2 · price: The price reported is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $4.72 - $4.76 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote to this Form 4. Read SEC document |
| March 24, 2022 Filed Apr 14, 2022 11:18 UTC | Immunovant, Inc. IMVT · Entity 3632 | SaleCommon Stock | 6,381 | $5.90 | $37,647.90 |
DisclosureSEC source: 0001764013-22-000037 · wf-form4_164993512439127.xml · nonDerivative · entry 1 Butchko Julia G. · CIK 0001796290 · Chief Dev. & Tech. Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 283,107 F1 · security: On March 19, 2021, the holder was granted 54,500 restricted stock units ("RSUs"), as previously reported on a Form 4 filed on March 23, 2021, of which 25% of these RSUs vested on March 19, 2022. Amounts reported herein represent shares sold by the holder solely to satisfy the holder's tax withholding obligation due in connection with the vesting and settlement of this tranche of the RSUs and do not represent a discretionary sale by the holder. Read SEC document |
| January 07, 2022 Filed Jan 11, 2022 15:58 UTC | Immunovant, Inc. IMVT · Entity 3632 | SaleCommon Stock | 55,318 | $7.25 | $401,055.50 |
DisclosureSEC source: 0001764013-22-000013 · wf-form4_164191666614109.xml · nonDerivative · entry 1 Butchko Julia G. · CIK 0001796290 · Chief Dev. & Tech. Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 289,488 F1 · security: On August 3, 2021, the holder was granted 285,306 restricted stock units ("RSUs"), as previously reported on a Form 4 filed on August 4, 2021, of which 50% of these RSUs vested on January 1, 2022. Amounts reported herein represent shares sold by the holder solely to satisfy the holder's tax withholding obligation due in connection with the vesting and settlement of this tranche of the RSUs. Read SEC document |
| September 11, 2021 Filed Sep 14, 2021 20:02 UTC | Immunovant, Inc. IMVT · Entity 3632 | Disposition to issuerStock Option (right to buy) · Derivative | 191,100 | $0.00 Strike: $17.00 | $0.00 |
DisclosureSEC source: 0001764013-21-000096 · wf-form4_163164971107075.xml · derivative · entry 4 Butchko Julia G. · CIK 0001796290 · Chief Dev. & Tech. Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 191,100 shares Expires 2031-03-19 F2 · derivative.exercise_date: Shares underlying the options vest over four years, with 25% of the shares underlying the options vesting on March 19, 2022 and the remainder of the shares underlying the options vesting in 36 equal monthly installments thereafter, subject to the Reporting Person providing continuous service to the Issuer as of each such date. Read SEC document |
| September 11, 2021 Filed Sep 14, 2021 20:02 UTC | Immunovant, Inc. IMVT · Entity 3632 | GrantStock Option (right to buy) · Derivative | 191,100 | $0.00 Strike: $8.62 | $0.00 |
DisclosureSEC source: 0001764013-21-000096 · wf-form4_163164971107075.xml · derivative · entry 3 Butchko Julia G. · CIK 0001796290 · Chief Dev. & Tech. Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 191,100 Underlying: Common Stock · 191,100 shares Expires 2031-03-19 F2 · derivative.exercise_date: Shares underlying the options vest over four years, with 25% of the shares underlying the options vesting on March 19, 2022 and the remainder of the shares underlying the options vesting in 36 equal monthly installments thereafter, subject to the Reporting Person providing continuous service to the Issuer as of each such date. Read SEC document |
| September 11, 2021 Filed Sep 14, 2021 20:02 UTC | Immunovant, Inc. IMVT · Entity 3632 | Disposition to issuerStock Option (right to buy) · Derivative | 319,700 | $0.00 Strike: $19.01 | $0.00 |
DisclosureSEC source: 0001764013-21-000096 · wf-form4_163164971107075.xml · derivative · entry 2 Butchko Julia G. · CIK 0001796290 · Chief Dev. & Tech. Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 319,700 shares Expires 2030-05-14 F1 · derivative.exercise_date: 25% of the shares underlying the options vested on May 15, 2021, and the remainder vested or vests in 36 equal monthly installments thereafter, subject to the Reporting Person providing continuous service to the Issuer as of each such date. Read SEC document |
| September 11, 2021 Filed Sep 14, 2021 20:02 UTC | Immunovant, Inc. IMVT · Entity 3632 | GrantStock Option (right to buy) · Derivative | 319,700 | $0.00 Strike: $8.62 | $0.00 |
DisclosureSEC source: 0001764013-21-000096 · wf-form4_163164971107075.xml · derivative · entry 1 Butchko Julia G. · CIK 0001796290 · Chief Dev. & Tech. Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 319,700 Underlying: Common Stock · 319,700 shares Expires 2030-05-14 F1 · derivative.exercise_date: 25% of the shares underlying the options vested on May 15, 2021, and the remainder vested or vests in 36 equal monthly installments thereafter, subject to the Reporting Person providing continuous service to the Issuer as of each such date. Read SEC document |
| August 03, 2021 Filed Aug 4, 2021 20:10 UTC | Immunovant, Inc. IMVT · Entity 3632 | GrantCommon Stock | 285,306 | $0.00 | $0.00 |
DisclosureSEC source: 0001764013-21-000069 · wf-form4_162810780822330.xml · nonDerivative · entry 1 Butchko Julia G. · CIK 0001796290 · Chief Dev. & Tech. Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 344,806 F1 · security: Represents the number of shares underlying restricted stock units awards ("RSUs"). F2 · shares: 50% of the RSUs will vest on January 1, 2022 and the remainder of the RSUs will vest on January 1, 2023, subject to the Reporting Person providing continuous service to the Issuer as of each such date. Read SEC document |
| March 19, 2021 Filed Mar 23, 2021 12:39 UTC | Immunovant, Inc. IMVT · Entity 3632 | GrantStock Option (right to buy) · Derivative | 191,100 | $0.00 Strike: $17.00 | $0.00 |
DisclosureSEC source: 0001764013-21-000036 · wf-form4_161650314745187.xml · derivative · entry 2 Butchko Julia G. · CIK 0001796290 · Chief Dev. & Tech. Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 191,100 Underlying: Common Stock · 191,100 shares Expires 2031-03-19 F3 · derivative.exercise_date: Shares underlying the options vest over four years, with 25% of the shares underlying the options vesting on March 19, 2022 and the remainder of the shares underlying the options vesting in 36 equal monthly installments thereafter, subject to the Reporting Person providing continuous service to the Issuer as of each such date. Read SEC document |
| March 19, 2021 Filed Mar 23, 2021 12:39 UTC | Immunovant, Inc. IMVT · Entity 3632 | GrantCommon Stock | 54,500 | $0.00 | $0.00 |
DisclosureSEC source: 0001764013-21-000036 · wf-form4_161650314745187.xml · nonDerivative · entry 1 Butchko Julia G. · CIK 0001796290 · Chief Dev. & Tech. Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 59,500 F1 · security: Represents the number of shares underlying restricted stock units awards ("RSUs"). F2 · shares: The RSUs vest over four years, with 25% of the RSUs vesting on March 19, 2022 and the remainder of the RSUs vesting in 36 equal monthly installments thereafter, subject to the Reporting Person providing continuous service to the Issuer as of each such date. Read SEC document |
| September 11, 2020 Filed Sep 15, 2020 21:09 UTC | Immunovant, Inc. IMVT · Entity 3632 | PurchaseCommon Stock | 5,000 | $38.17 | $190,850.00 |
DisclosureSEC source: 0001764013-20-000037 · wf-form4_160020415457284.xml · nonDerivative · entry 1 Butchko Julia G. · CIK 0001796290 · Chief Dev. & Tech. Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,000 Read SEC document |
| May 15, 2020 Filed May 18, 2020 12:22 UTC | Immunovant, Inc. IMVT · Entity 3632 | GrantStock Option (right to buy) · Derivative | 319,700 | $0.00 Strike: $19.01 | $0.00 |
DisclosureSEC source: 0001209191-20-029924 · doc4.xml · derivative · entry 1 Butchko Julia G. · CIK 0001796290 · Chief Dev. & Tech. Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 319,700 Underlying: Common Stock · 319,700 shares Expires 2030-05-14 F1 · derivative.exercise_date: 25% of the shares underlying the option vests on the first anniversary of the grant date, and the remainder vests in 36 equal monthly installments thereafter, subject to the Reporting Person providing continuous service to the Issuer as of each such date. Read SEC document |
| December 18, 2019 Filed Dec 20, 2019 21:48 UTC | Immunovant, Inc. IMVT · Entity 3632 | GrantStock Option (right to buy) · Derivative | 433,588 | Not disclosed Strike: $8.43 | Not disclosed |
DisclosureSEC source: 0001209191-19-061584 · doc4.xml · derivative · entry 1 Butchko Julia G. · CIK 0001796290 · Chief Dev. & Tech. Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 433,588 Underlying: Common Stock · 433,588 shares Expires 2029-11-19 F2 · price: In connection with the share exchange transaction pursuant to which Health Sciences Acquisitions Corporation ("HSAC") acquired 100% of the issued and outstanding shares of Immunovant Sciences Ltd., the option to purchase 886,563 shares of Immunovant Sciences Ltd. at exercise price of $4.12 per share, was assumed by HSAC and converted into an option to purchase shares of the Issuer (formerly known as HSAC). F1 · derivative.exercise_date: 25% of the shares underlying the option vests on the first anniversary of the grant date, and the remainder vests in 12 equal quarterly installments thereafter. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.